Table 6.
Symptom | Treatment | Description |
---|---|---|
Fatigue | Modafinil | RCT failed to show efficacy |
Pruritus | Anion-exchange resins (cholestyramine) | The first-line treatment, despite limitations |
Rifampicin | The second-line treatment | |
µ-opioid receptor antagonists (naloxone or naltrexone) | The second-line treatment | |
κ-opioid receptor agonist (nalfurafine hydrochloride) | Approved only in Japan | |
Ileal bile acid transporter inhibitor | Linerixibat; efficacy was shown in the Phase 2a; now global phase 2b (NCT02966834) | |
Maralixibat; failed to show efficacy | ||
Bezafibrate | Now being investigated (NCT02701166) | |
Sicca syndrome | Artificial tears and saliva | Should be initially used |
Pilocarpine or cevimeline | May be helpful in refractory cases |
PBC, primary biliary cholangitis; RCT, randomized clinical trial.